Q4 2024 Sangamo Therapeutics Inc Earnings Call Transcript
Key Points
- Sangamo Therapeutics Inc (SGMO) has advanced its neurology therapies, securing its first neurology IND for idiopathic small fiber neuropathy.
- The company has established collaborations with Genentech and Astellas for neurotropic capsids, enhancing its industry partnerships.
- Sangamo has a clear regulatory pathway to accelerated approval for its Fabry disease gene therapy, potentially reducing approval time by three years.
- The company has significantly reduced its non-GAAP operating expenses by nearly half year over year.
- Sangamo raised over $100 million in funding through non-dilutive license fees, milestone payments, and equity financing in 2024.
- Sangamo Therapeutics Inc (SGMO) is still in the process of securing a commercial partner for its Fabry program, which is proving to be time-consuming.
- The company is facing financial challenges and emphasizes the need to secure additional capital to continue its operations.
- There is uncertainty regarding the completion of a third STAC-BBB license agreement, which is still in late-stage negotiations.
- The company has not yet finalized a partnership for its hemophilia program after Pfizer's termination notice.
- Sangamo's future plans and expectations are heavily dependent on securing adequate additional funding.
Good afternoon and welcome to the Sangamo Therapeutics fourth-quarter and full year 2024 teleconference call. Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your speaker (technical difficulty) Please go ahead.
Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo executive leadership team, including Sandy McCray, Chief Executive Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; and Prathyusha Duraibabu, Chief Financial Officer.
Slides from our corporate presentation can be found on our website, sangamo.com, and under the presentations page of the Investors and Media section.
This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements related to Sangamo's cash runway, plans to obtain additional capital, and ability to continue operating
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
